Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a phase III study

Last Updated: Thursday, January 18, 2024

This clinical trial update presents the final prespecified overall survival analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). It was found that lenvatinib plus pembrolizumab achieved consistent, durable benefit with a manageable safety profile in these patients.

Journal of Clinical Oncology

Academic Radiology

Is ablation suitable for small renal masses (SRMs)? A meta-analysis

Current Oncology

Impact of timing of immunotherapy and cytoreductive nephrectomy in metastatic renal cell carcinoma: Real-world data on survival outcomes from the CKCis database

Journal of Kidney Cancer and VHL

Clinical outcomes for metastatic renal cell carcinoma (mRCC) patients ineligible for front-line clinical trials

Urologic Oncology

Socioeconomic and demographic disparities in immunotherapy utilization for advanced kidney and bladder cancer

The Spanish Journal of Gastroenterology

Clear cell renal cancer metastasis - A case of delayed diagnosis

Urologic Oncology

First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety

BMC Nephrology

Renal cell carcinoma in a transplanted kidney: A retrospective evaluation

BMC Urology

Composite eosinophilic solid and cystic renal cell carcinoma and clear cell renal cell carcinoma: A rare case report and literature review

American Journal of Cancer Research

Characterization and verification of MMP family members as potential biomarkers in kidney clear cell renal carcinoma

Cancers

Recent advances in single-cell RNA-sequencing of primary and metastatic clear cell renal cell carcinoma

Renal Cell Carcinoma Resource Center

Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a phase III study

Academic Radiology

Is ablation suitable for small renal masses (SRMs)? A meta-analysis

Current Oncology

Impact of timing of immunotherapy and cytoreductive nephrectomy in metastatic renal cell carcinoma: Real-world data on survival outcomes from the CKCis database

Journal of Kidney Cancer and VHL

Clinical outcomes for metastatic renal cell carcinoma (mRCC) patients ineligible for front-line clinical trials

Urologic Oncology

Socioeconomic and demographic disparities in immunotherapy utilization for advanced kidney and bladder cancer

The Spanish Journal of Gastroenterology

Clear cell renal cancer metastasis - A case of delayed diagnosis

Urologic Oncology

First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety

BMC Nephrology

Renal cell carcinoma in a transplanted kidney: A retrospective evaluation

BMC Urology

Composite eosinophilic solid and cystic renal cell carcinoma and clear cell renal cell carcinoma: A rare case report and literature review

American Journal of Cancer Research

Characterization and verification of MMP family members as potential biomarkers in kidney clear cell renal carcinoma

Cancers

Recent advances in single-cell RNA-sequencing of primary and metastatic clear cell renal cell carcinoma

First-Line Metastatic Renal Cell Carcinoma

Patient Diagnosed With Clear Cell Renal Cell Carcinoma

Younger Patient With Stage III Chromophobe RCC